MedTrace Logo

Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection

NCT00000587 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-11-26

No results posted yet for this study

Summary

To determine whether administration of human recombinant erythropoietin (REPO) improved or eliminated the anemia seen in human immunodeficiency virus (HIV) infected patients after therapy with zidovudine (ZDV).

Conditions

Interventions

PROCEDURE

erythropoietin, recombinant

Sponsors & Collaborators

  • Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Stephen Hauptman · Jefferson Medical College of Thomas Jefferson University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1988-09-30
Primary Completion
2005-01-31
Completion
2005-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000587 on ClinicalTrials.gov